Nuclear Receptor News

Nuclear Receptor News http://nuclearreceptorcentral.wordpress.com Sat, 01 Nov 2008 16:43:16 +0000 en hourly 1 http://wordpress.com/ http://s2.wp.com/i/buttonw-com.png Nuclear Receptor News http://nuclearreceptorcentral.wordpress.com QLT initiate Phase I trial of retinoid QLT091001 http://nuclearreceptorcentral.wordpress.com/2008/11/01/qlt-initiate-phase-i-trial-of-retinoid-qlt091001/ http://nuclearreceptorcentral.wordpress.com/2008/11/01/qlt-initiate-phase-i-trial-of-retinoid-qlt091001/#comments Sat, 01 Nov 2008 16:43:16 +0000 crimsoncanary http://nuclearreceptorcentral.wordpress.com/?p=152 ]]> QLT has initiated a Phase I safety retinoid QLT091001, that has potential in the treatment of Leber’s Congenital Amaurosis (LCA)

]]> http://nuclearreceptorcentral.wordpress.com/2008/11/01/qlt-initiate-phase-i-trial-of-retinoid-qlt091001/feed/ 0 crimsoncanary Zydus publish series of PPAR alpha agonists http://nuclearreceptorcentral.wordpress.com/2008/11/01/zydus-publish-series-of-ppar-alpha-agonists/ http://nuclearreceptorcentral.wordpress.com/2008/11/01/zydus-publish-series-of-ppar-alpha-agonists/#comments Sat, 01 Nov 2008 16:27:23 +0000 crimsoncanary http://nuclearreceptorcentral.wordpress.com/?p=150 ]]>

Zydus have published a series of glycine and oximinobutyric acid PPARα agonists

]]> http://nuclearreceptorcentral.wordpress.com/2008/11/01/zydus-publish-series-of-ppar-alpha-agonists/feed/ 0 crimsoncanary Cytochroma initiate Phase II trial of Vitamin D analog CTA018 in Chronic kidney disease http://nuclearreceptorcentral.wordpress.com/2008/10/24/cytochroma-initiate-phase-ii-trial-of-vitamin-d-analog-cta018-in-chronic-kidney-disease/ http://nuclearreceptorcentral.wordpress.com/2008/10/24/cytochroma-initiate-phase-ii-trial-of-vitamin-d-analog-cta018-in-chronic-kidney-disease/#comments Fri, 24 Oct 2008 17:21:05 +0000 crimsoncanary http://nuclearreceptorcentral.wordpress.com/?p=148 ]]> Cytochroma have initiated a Phase II clinical trial of Vitamin D analog CTA018 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD).

]]> http://nuclearreceptorcentral.wordpress.com/2008/10/24/cytochroma-initiate-phase-ii-trial-of-vitamin-d-analog-cta018-in-chronic-kidney-disease/feed/ 0 crimsoncanary Galderma and Shionogi Launch Differin gel for acne vulgaris http://nuclearreceptorcentral.wordpress.com/2008/10/14/galderma-and-shionogi-launch-differin-gel-for-acne-vulgaris/ http://nuclearreceptorcentral.wordpress.com/2008/10/14/galderma-and-shionogi-launch-differin-gel-for-acne-vulgaris/#comments Tue, 14 Oct 2008 18:00:45 +0000 crimsoncanary http://nuclearreceptorcentral.wordpress.com/?p=146 ]]> Galderma and Shionogi have scheduled their launch Differin® Gel 0.1% (Adapalen) for acne vulgaris on October 21, 2008.

]]> http://nuclearreceptorcentral.wordpress.com/2008/10/14/galderma-and-shionogi-launch-differin-gel-for-acne-vulgaris/feed/ 0 crimsoncanary Ostarine (MK-2866) meets primary endpoint in Phase II Cancer Cachexia Trial http://nuclearreceptorcentral.wordpress.com/2008/10/14/ostarine-mk-2866-meets-primary-endpoint-in-phase-ii-cancer-cachexia-trial/ http://nuclearreceptorcentral.wordpress.com/2008/10/14/ostarine-mk-2866-meets-primary-endpoint-in-phase-ii-cancer-cachexia-trial/#comments Tue, 14 Oct 2008 17:40:54 +0000 crimsoncanary http://nuclearreceptorcentral.wordpress.com/?p=144 ]]> GTx have announced Phase II results of SARM Ostarine (MK-2866) in patients with cancer cachexia. The study met its primary endpoint of absolute change in total lean body mass (muscle) compared to placebo.

]]> http://nuclearreceptorcentral.wordpress.com/2008/10/14/ostarine-mk-2866-meets-primary-endpoint-in-phase-ii-cancer-cachexia-trial/feed/ 0 crimsoncanary Basileas Toctino approved in Germany for eczema (atopic dermatitis) http://nuclearreceptorcentral.wordpress.com/2008/10/06/basileas-toctino-approved-in-germany-for-eczema-atopic-dermatitis/ http://nuclearreceptorcentral.wordpress.com/2008/10/06/basileas-toctino-approved-in-germany-for-eczema-atopic-dermatitis/#comments Mon, 06 Oct 2008 15:04:37 +0000 crimsoncanary http://nuclearreceptorcentral.wordpress.com/?p=142 ]]> Basilea Pharmaceutica have announced that Toctino (alitretinoin) has been approved by the German health authority “Bundesinstitut für Arzneimittel und Medizinprodukte” for the treatment of eczema (atopic dermatitis)

]]> http://nuclearreceptorcentral.wordpress.com/2008/10/06/basileas-toctino-approved-in-germany-for-eczema-atopic-dermatitis/feed/ 0 crimsoncanary Dara Biosciences completes Tox studies for PPAR-delta/gamma agonist, DB959 http://nuclearreceptorcentral.wordpress.com/2008/10/02/dara-biosciences-completes-tox-studies-for-ppar-deltagamma-agonist-db959/ http://nuclearreceptorcentral.wordpress.com/2008/10/02/dara-biosciences-completes-tox-studies-for-ppar-deltagamma-agonist-db959/#comments Thu, 02 Oct 2008 20:28:11 +0000 crimsoncanary http://nuclearreceptorcentral.wordpress.com/?p=140 ]]> DARA BioSciences has completed all toxicology studies necessary for entering Phase 1 clinical trials for its PPAR-delta/gamma agonist, DB959.

]]> http://nuclearreceptorcentral.wordpress.com/2008/10/02/dara-biosciences-completes-tox-studies-for-ppar-deltagamma-agonist-db959/feed/ 0 crimsoncanary GSK publish series of PPAR α/γ dual activators http://nuclearreceptorcentral.wordpress.com/2008/10/02/gsk-publish-series-of-ppar-%ce%b1%ce%b3-dual-activators/ http://nuclearreceptorcentral.wordpress.com/2008/10/02/gsk-publish-series-of-ppar-%ce%b1%ce%b3-dual-activators/#comments Thu, 02 Oct 2008 20:22:56 +0000 crimsoncanary http://nuclearreceptorcentral.wordpress.com/?p=137 ]]> GSK have published a series of equipotent PPAR α/γ dual activators

]]> http://nuclearreceptorcentral.wordpress.com/2008/10/02/gsk-publish-series-of-ppar-%ce%b1%ce%b3-dual-activators/feed/ 0 crimsoncanary Dong-A publish series of PPAR alpha/gamma dual agonists http://nuclearreceptorcentral.wordpress.com/2008/10/01/dong-a-publish-series-of-ppar-alphagamma-dual-agonists/ http://nuclearreceptorcentral.wordpress.com/2008/10/01/dong-a-publish-series-of-ppar-alphagamma-dual-agonists/#comments Wed, 01 Oct 2008 14:37:59 +0000 crimsoncanary http://nuclearreceptorcentral.wordpress.com/?p=135 ]]> Dong-A have published a series of diaryl α-ethoxy propanoic acid PPAR alpha/gamma dual agonists

]]> http://nuclearreceptorcentral.wordpress.com/2008/10/01/dong-a-publish-series-of-ppar-alphagamma-dual-agonists/feed/ 0 crimsoncanary FDA/Indevus agree on path forward for Nebido http://nuclearreceptorcentral.wordpress.com/2008/09/30/fdaindevus-agree-on-path-forward-for-nebido/ http://nuclearreceptorcentral.wordpress.com/2008/09/30/fdaindevus-agree-on-path-forward-for-nebido/#comments Tue, 30 Sep 2008 13:53:09 +0000 crimsoncanary http://nuclearreceptorcentral.wordpress.com/?p=132 ]]> Indevus Pharmaceuticals has reached agreement with the FDA in regard to additional data and risk management required to allow re-submission of its NDA for its testosterone product Nebido in the treatment of hypogonadism

]]> http://nuclearreceptorcentral.wordpress.com/2008/09/30/fdaindevus-agree-on-path-forward-for-nebido/feed/ 0 crimsoncanary